Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: The IMMEDIATE trial

K. L. Ellis, Y. Zhou, J. R. Beshansky, E. Ainehsazan, Y. Yang, H. P. Selker, G. S. Huggins, L. A. Cupples, I. Peter

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

The mechanistic effects of intravenous glucose, insulin and potassium (GIK) in cardiac ischemia are not well understood. We conducted a genetic sub-study of the Immediate Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care (IMMEDIATE) Trial to explore effects of common and rare glucose and insulin-related genetic loci on initial to 6-h and 6- to 12-h change in plasma glucose and potassium. We identified 27 NOTCH2/ADAM30 and 8 C2CD4B variants conferring a 40-57% increase in glucose during the first 6 h of infusion (P<5.96 × 10-6). Significant associations were also found for ABCB11 and SLC30A8 single-nucleotide polymorphisms (SNPs) and glucose responses, and an SEC61A2 SNP with a potassium response to GIK. These studies identify genetic factors that may impact the metabolic response to GIK, which could influence treatment benefits in the setting of acute coronary syndromes (ACS).

Original languageEnglish
Pages (from-to)55-62
Number of pages8
JournalPharmacogenomics Journal
Volume15
Issue number1
DOIs
StatePublished - 28 Feb 2015

Fingerprint

Dive into the research topics of 'Genetic variation at glucose and insulin trait loci and response to glucose-insulin-potassium (GIK) therapy: The IMMEDIATE trial'. Together they form a unique fingerprint.

Cite this